Received Feb 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | Y012077 | — |
HCP calling to report an AE regarding the PROQUAD vaccine. HCP reported that a 14 year old female patient was administered a dose of the PROQUAD vaccine. HCP did not report any side effects from the administration of the PROQUAD vaccine. HCP did not; HCP did not report any side effects from the administration of the PROQUAD vaccine.; This spontaneous report was received from registered nurse (RN) concerning to a 14-year-old female patient. Her medical history, concurrent conditions, concomitant therapies, and drug reactions/allergies were not reported. On an unknown date, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live recombinant Human Albumin (rHA) (PROQUAD) injection, lot #Y012077, expiration date 05-JAN-2026 (exact dose, dosage regimen, anatomical location and route of administration were not provided) administered as prophylaxis (product administered to patient of inappropriate age.) The reporter did not inform any side effects from the administration of the measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) vaccine (no adverse event), did not state the reason for the administration of the vaccine and provided limited pertinent information and demographic data.